Table 3.
NR < 1.0 | NR > 1.0 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Survivors (n = 27) | Non-survivors (n = 6) | p value | Survivors (n = 7) | Non-survivors (n = 6) | p value | |||||
sPAP, mmHga | 33 | ± 10* | 51 | ± 32 | 0.015 | 42 | ± 14* | 61 | ± 30 | 0.16 |
TAPSE, mma | 16 | ± 3* | 16 | ± 3* | 0.84 | 16 | ± 3 | 15 | ± 2 | 0.47 |
TAPSE/sPAP, mm/mmHga | 0.55 | ± 0.21* | 0.47 | ± 0.24 | 0.45 | 0.43 | ± 0.17 | 0.26 | ± 0.12 | 0.10 |
RVEDD, cma | 3.4 | ± 0.63* | 3.4 | ± 0.46* | 0.83 | 3.7 | ± 0.81* | 4.1 | ± 0.55 | 0.45 |
PAAT, msa | 95 | ± 20* | 74 | ± 28 | 0.064 | 89 | ± 16* | 92 | ± 37 | 0.87 |
NR notch ratio, sPAP systolic pulmonary artery pressure, TAPSE tricuspid annular plane systolic excursion, RVEDD right ventricular end-diastolic diameter, PAAT pulmonary artery acceleration time
aMean ± SD
*p < 0.05 post-operative vs. pre-operative within group